GenmabGMAB.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, Genmab (GMAB.O) trades at a P/E of 29.30x, P/B of 3.88x, P/S of 5.59x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 42nd percentile over the trailing 10Y window (vs. 86th percentile over 3Y); P/B sits at the 29th percentile over the trailing 10Y window (vs. 71st percentile over 3Y); P/S sits at the 27th percentile over the trailing 10Y window (vs. 60th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 59th percentile within its industry and the 68th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.86%, ranking at the 76th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 13.0 points, pointing to a consistent valuation read across both metrics. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Genmab operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: GMAB · GMAB
Want the full picture on whether Genmab (GMAB.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 29.30 | ||||||
| P/B (MRQ) | 3.88 | ||||||
| P/S (TTM) | 5.59 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 1.86% |